Novavax (MEX:NVAX) Long-Term Debt : MXN3,539 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Novavax Long-Term Debt?

Novavax's Long-Term Debt for the quarter that ended in Dec. 2024 was MXN3,539 Mil.

Novavax's quarterly Long-Term Debt increased from Jun. 2024 (MXN3,093 Mil) to Sep. 2024 (MXN3,333 Mil) and increased from Sep. 2024 (MXN3,333 Mil) to Dec. 2024 (MXN3,539 Mil).

Novavax's annual Long-Term Debt declined from Dec. 2022 (MXN3,245 Mil) to Dec. 2023 (MXN2,852 Mil) but then increased from Dec. 2023 (MXN2,852 Mil) to Dec. 2024 (MXN3,539 Mil).

Novavax Long-Term Debt Historical Data

The historical data trend for Novavax's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Long-Term Debt Chart

Novavax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

6,405.92

6,635.42

3,245.42

2,851.95

3,538.88

Novavax Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															2,851.95	2,795.34	3,093.31	3,332.88	3,538.88

Novavax (MEX:NVAX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Novavax Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Novavax's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (MEX:NVAX) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria NVAX:Austria

Address

700 Quince Orchard Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.